ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis
September 25, 2017 16:00 ET
|
ProQR Therapeutics N.V.
Key updates QR-010 was observed to be safe and well-tolerated across all doses in this trial with no serious adverse events related to treatment.A clinically meaningful improvement of CF respiratory...
ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology
September 21, 2017 07:05 ET
|
ProQR Therapeutics N.V.
Key updates ProQR presents in vivo data in a relevant disease model, establishing proof of concept for its novel and proprietary Axiomer® RNA editing platform technology.Axiomer® technology Editing...
ProQR to Present at Two Investor Conferences in September
September 21, 2017 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Sept. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Company will present at two investor conferences during the month of...
ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong
August 28, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates ProQR appoints three new members to the Company’s Scientific Advisory Board: Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong, who bring a tremendous amount of experience in the...